RedHill Bio doses first COVID-19 patient with Opaganib in Israel; shares up 9% premarket

April 6, 2020
  • RedHill Biopharma (NASDAQ:RDHL) has dosed the first patient with COVID-19 infection with its IND, opaganib (Yeliva, ABC294640), in Israel.
  • The treatment is administered under a compassionate use program in accordance with the Israeli Ministry of Health guidelines, with additional patients expected to be treated in coming days.
  • RedHill is also preparing for potential ramp-up of manufacturing of opaganib.
  • Shares are up 9% premarket.

Read original article here.

Posted in Blog